2. Academic Validation
  3. Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review

Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review

  • Vasc Med. 2024 Feb;29(1):85-92. doi: 10.1177/1358863X231206778.
Swathi Prakash 1,  Adriana C Mares 1 2,  Mateo Porres-Aguilar 3,  Debabrata Mukherjee 4,  Geoffrey D Barnes 5
Affiliations

Affiliations

  • 1 Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
  • 2 Yale University School of Medicine, New Haven, CT, USA.
  • 3 Department of Internal Medicine, Divisions of Hospital and Adult Thrombosis Medicine, Texas Tech University Health Sciences Center and Paul L Foster School of Medicine, El Paso, TX, USA.
  • 4 Division of Cardiovascular Diseases, Texas Tech University Health Sciences Center and Paul L Foster School of Medicine, El Paso, TX, USA.
  • 5 Department of Internal Medicine, Division of Cardiovascular Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, USA.
PMID: 37947131 DOI: 10.1177/1358863X231206778
Abstract

During the past decade, direct oral anticoagulants (DOACs) have advanced and simplified the prevention and treatment of venous thromboembolism (VTE). However, there remains a high incidence of bleeds, which calls for agents that have a reduced risk of bleeding. Factor XI (FXI) deficiency is associated with lower rates of venous thrombosis and stroke compared to the general population with a lower risk of bleeding. In conjunction with this, phase 2 studies have demonstrated safety and the potential for reduced thrombotic events with FXI inhibitors as compared to currently available medications. The aim of this review is to summarize key data on the clinical pharmacology of FXI, the latest developments in clinical trials of FXI inhibitors, and to describe the efficacy and safety profiles of FXI inhibitors for the prevention of venous and arterial thromboembolism.

Keywords

anticoagulation; bleeding events; factor XI; thromboprophylaxis; thrombosis; venous thromboembolism (VTE).

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z